114 related articles for article (PubMed ID: 4434291)
1. Effects of levodopa therapy in Parkinson's disease. II. Measurement of behavioural changes.
Radbill R; Rosenberg G; Schwartz A
Can Med Assoc J; 1974 Dec; 111(11):1218-22. PubMed ID: 4434291
[TBL] [Abstract][Full Text] [Related]
2. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
3. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
4. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
6. Dementia and treatment with L-dopa in Parkinson's disease.
Hietanen M; Teräväinen H
Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
[TBL] [Abstract][Full Text] [Related]
7. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
[TBL] [Abstract][Full Text] [Related]
8. Subtypes of Parkinson's disease defined by intellectual impairment.
Mortimer JA; Jun SP; Kuskowski MA; Webster DD
J Neural Transm Suppl; 1987; 24():101-4. PubMed ID: 3479520
[TBL] [Abstract][Full Text] [Related]
9. Levodopa and executive performance in Parkinson's disease: a randomized study.
Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychological and motor functioning after unilateral anatomically guided posterior ventral pallidotomy. Preoperative performance and three-month follow-up.
Cahn DA; Sullivan EV; Shear PK; Heit G; Lim KO; Marsh L; Lane B; Wasserstein P; Silverberg GD
Neuropsychiatry Neuropsychol Behav Neurol; 1998 Jul; 11(3):136-45. PubMed ID: 9742512
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
[TBL] [Abstract][Full Text] [Related]
13. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
[TBL] [Abstract][Full Text] [Related]
14. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
15. [Levodopa and cognitive disorders in Parkinson's disease].
Leiva-Santana C; Alvarez-Saúco M
Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
[TBL] [Abstract][Full Text] [Related]
16. Dopamine and memory function in Parkinson's disease.
Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase TN
Mov Disord; 1989; 4(2):113-20. PubMed ID: 2543918
[TBL] [Abstract][Full Text] [Related]
17. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease.
Funkiewiez A; Ardouin C; Cools R; Krack P; Fraix V; Batir A; Chabardès S; Benabid AL; Robbins TW; Pollak P
Mov Disord; 2006 Oct; 21(10):1656-62. PubMed ID: 16830317
[TBL] [Abstract][Full Text] [Related]
18. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
19. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
20. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Hironishi M; Miwa H; Kondo T
No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]